Used in cancer immunotherapy to block the TIGIT receptor on immune cells, enhancing the body's immune response against tumors. It works by preventing the suppression of T-cell activity, allowing the immune system to more effectively recognize and destroy cancer cells. Commonly studied in combination with PD-1/PD-L1 inhibitors for treating non-small cell lung cancer and other solid tumors. Supports research and development of biologics in oncology, serving as a reference standard in assay validation and antibody characterization.